New cocktail of cancer drugs shows promise for Tough-to-Treat sarcoma
NCT ID NCT06820957
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approach delays cancer growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vincristine, irinotecan, regorafenib, doxorubicin, cyclophosphamide, ifosfamide, etoposide
What this could lead to
If successful, this could offer a more effective treatment option for people with metastatic Ewing sarcoma, potentially improving survival rates.
What could go wrong
This is an early-to-mid-stage trial, so the new drug combo may not work better than standard treatment. Side effects from the multiple chemotherapy drugs could be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROUND CELL SARCOMA WITH EWSR1-NON-ETS FUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BI-LO Charities Children's Cancer Center
Greenville, South Carolina, 29605, United States
-
Children's Hospital of Alabama
Birmingham, Alabama, 35233, United States
-
East Tennessee Childrens Hospital
Knoxville, Tennessee, 37916, United States
-
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826, United States
-
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611, United States
-
NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
OSF Children's Hospital of Illinois
Peoria, Illinois, 61637, United States
-
Prisma Health Richland Hospital
Columbia, South Carolina, 29203, United States
-
Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134, United States